Inspire Medical Systems, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 9, 2024. This is an annual report, not a standalone Q4 report. The filing does not provide a clear set of Q4-only financial results.
Business context
Inspire develops and sells an implantable, closed-loop neurostimulation system for eligible patients with moderate-to-severe obstructive sleep apnea who cannot tolerate or do not benefit from PAP therapy. Revenue is generated primarily from Inspire system sales. The company reported one operating segment; 97% of FY2023 revenue came from the U.S.
Key financial metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $624.8 million | $407.9 million | +53.2% |
| Gross profit / margin | $528.2 million / 84.5% | $341.7 million / 83.8% | Margin +0.7 percentage points |
| Operating expenses | $568.5 million | $389.3 million | +46.0% |
| Operating loss | $40.3 million | $47.6 million | Loss narrowed |
| Net loss | $21.2 million | $44.9 million | Loss narrowed |
| Net cash from operations | $24.7 million | $11.6 million | Increased |
| Cash, cash equivalents and investments | $469.5 million | $451.4 million | + $18.1 million |
FY2023 basic and diluted loss per share was $0.72. Cash and cash equivalents were $185.5 million, with short- and long-term investments of $284.0 million. Working capital was $515.6 million. The company had no outstanding borrowings at year-end; its former credit facility was repaid in 2022. FY2023 investing cash outflow was $294.8 million, mainly reflecting purchases of investments and $23.6 million of property and equipment.
Changes and notable developments
- Revenue growth reflected greater penetration in existing territories, expansion into new territories, increased awareness and, to a lesser extent, a prior-year price increase. U.S. revenue rose 53.5%; revenue outside the U.S. rose 43.0%.
- R&D expense increased 69.8% to $116.5 million, and SG&A increased 40.9% to $452.0 million, reflecting increased staffing, product development and marketing. Advertising expense was $100.3 million, versus $74.3 million in 2022.
- Operating cash flow improved despite the net loss, supported in part by non-cash expenses, including $82.5 million of stock-based compensation.
- The company expanded its FDA indication to AHI up to 100 events per hour and raised the BMI warning to 40; it also received FDA approval for certain pediatric patients with Down syndrome and for its SleepSync physician programmer. A PMA supplement for the next-generation system was submitted in 2023.
Outlook, risks and contingencies
- Management expects FY2024 gross margin of 83%–85%, continued significant R&D spending and further increases in capital expenditures. It says year-end liquidity, together with operating cash flows, is expected to fund operations and planned capital expenditures for at least 12 months.
- European lead supply and certification remain important risks. Delayed EU MDR certification for silicone leads and limited polyurethane-lead supply contributed to delayed procedures; the estimated Q4 2023 European revenue impact was approximately $4 million. Management anticipated further procedure delays, with improvement dependent in part on certification and existing country derogations.
- Management cited ENT surgeon capacity constraints and prior-authorization process changes as factors affecting revenue growth. It also identified seasonality, reimbursement and coverage changes, competition, reliance on single-source suppliers, and macroeconomic and supply-chain conditions as risks.
- A putative securities class action filed in December 2023 alleges misleading statements about the Acceleration Program and prior-authorization assistance. The company says it considers the allegations without merit and intends to defend the case; claimed damages are unquantified.
- The company has incurred losses since inception and reported an accumulated deficit of $345.4 million. Management cautions that expenses may continue to rise and profitability is not assured.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Inventory valuation reserves were identified as a critical audit matter.
Investor verification priorities
- Track FY2024 revenue growth and procedure volumes, separating underlying demand from European supply-related constraints and surgeon capacity.
- Verify timing and scope of EU MDR certification for silicone leads, the status of country derogations, and whether polyurethane supply continues to limit procedures.
- Assess whether higher commercial, R&D and stock-based compensation costs can be supported by growth while margins remain within the stated outlook.
- Review reimbursement coverage, prior-authorization performance and developments in the Acceleration Program lawsuit.
- Monitor inventory growth and reserve assumptions, supplier concentration, and the company’s ability to convert operating growth into sustained positive cash flow.